Keymed Biosciences Reports Impressive Interim Results for 2025 with Accelerated Commercialization and R&D Momentum Keymed Biosciences Inc. has reported significant interim results for 2025, showcasing strong commercialization and innovative research developments that stand out in the biotech sector.

Keymed Biosciences Reports Impressive Interim Results for 2025 with Accelerated Commercialization and R&D Momentum #China #Chengdu #Keymed_Biosciences #CMG901 #Kang_Yue_Da